Brexit’s impact on the UK’s medical landscape could be significant, with the potential to interrupt the supply of medical cannabis for some patients in the country. This concern arises from the fact that once Brexit is finalized, the UK will no longer be a part of the European Union’s single market and customs union. This detachment could result in new tariffs and regulatory frameworks being imposed on the importation of medical cannabis from countries affiliated with the EU. Despite this potential challenge, the UK government has consistently asserted its commitment to guaranteeing that patients continue to have access to essential medicines post-Brexit. Nonetheless, there remains a shroud of uncertainty as to how this pledge will be materialized in a pragmatic context. The government has disclosed that it is liaising with the pharmaceutical sector to formulate a strategy for the import of medicines post-Brexit. However, it remains hazy how this strategy will accommodate the specific needs of medical cannabis, a product that is relatively new and caters to a niche market. There are existing challenges for some patients in the UK who are already grappling with difficulties in accessing medical cannabis. This was exacerbated in 2021 when the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) declared that it would no longer be accepting applications for new medical cannabis products from companies not based in the UK. This decision has created a significant hurdle for patients seeking access to new medical cannabis products, even if those products have previously been approved in other countries. This situation has led to heightened concerns among those directly affected. For instance, a news article highlighted the story of a father with an epileptic son. The father voiced his fears that Brexit could further complicate his son’s ability to access the necessary medication for his condition. He is urging the UK government to take definitive action to ensure that people have access to medical cannabis post-Brexit. In light of these concerns, it is imperative that the UK government takes decisive steps to guarantee patients continue to have access to medical cannabis after Brexit. Possible measures could include negotiating a deal with the EU that promotes free movement of medical cannabis between the UK and the EU, developing a clear and transparent import strategy for medical cannabis post-Brexit, and allocating funds for research into medical cannabis and its therapeutic potential. Additionally, the government could consider streamlining the approval process for companies looking to market medical cannabis products in the UK. By implementing these measures, the UK government can alleviate concerns and ensure that patients continue to have access to the medical cannabis they need, regardless of the changes brought about by Brexit. In this way, the government can uphold its commitment to the health and well-being of its citizens, demonstrating that despite the political shift, public health remains a priority.